Coronary Vasomotor Abnormalities in Insulin-Resistant Individuals

  1. Manuel J. Quiñones, MD;
  2. Miguel Hernandez-Pampaloni, MD, PhD;
  3. Heinrich Schelbert, MD, PhD;
  4. Isabel Bulnes-Enriquez, MD;
  5. Xochitl Jimenez, MD;
  6. Gustavo Hernandez, MD;
  7. Roxana De La Rosa, BS;
  8. Yun Chon, PhD;
  9. Huiying Yang, MD, PhD;
  10. Susanne B. Nicholas, MD, PhD;
  11. Tamara Modilevsky, MD;
  12. Katherine Yu, MD;
  13. Katja Van Herle, MD;
  14. Lawrence W. Castellani, PhD;
  15. Robert Elashoff, PhD; and
  16. Willa A. Hsueh, MD
  1. From University of California, Los Angeles, Los Angeles; Cedars-Sinai Medical Center, Los Angeles; and Olive View–University of California, Los Angeles Medical Center, Sylmar, California.

    Abstract

    Background: Insulin resistance is a metabolic spectrum that progresses from hyperinsulinemia to the metabolic syndrome, impaired glucose tolerance, and finally type 2 diabetes mellitus. It is unclear when vascular abnormalities begin in this spectrum of metabolic effects.

    Objective: To evaluate the association of insulin resistance with the presence and reversibility of coronary vasomotor abnormalities in young adults at low cardiovascular risk.

    Design: Cross-sectional study followed by prospective, open-label treatment study.

    Setting: University hospital.

    Patients: 50 insulin-resistant and 22 insulin-sensitive, age-matched Mexican-American participants without glucose intolerance or traditional risk factors for or evidence of coronary artery disease.

    Intervention: 3 months of thiazolidinedione therapy for 25 insulin-resistant patients.

    Measurements: Glucose infusion rate in response to insulin infusion was used to define insulin resistance (glucose infusion rate ≤ 4.00 mg/kg of body weight per minute [range, 0.90 to 3.96 mg/kg per minute]) and insulin sensitivity (glucose infusion rate ≥ 7.50 mg/kg per minute [range, 7.52 to 13.92 mg/kg per minute]). Myocardial blood flow was measured by using positron emission tomography at rest, during cold pressor test (largely endothelium-dependent), and after dipyridamole administration (largely vascular smooth muscle–dependent).

    Results: Myocardial blood flow responses to dipyridamole were similar in the insulin-sensitive and insulin-resistant groups. However, myocardial blood flow response to cold pressor test increased by 47.6% from resting values in insulin-sensitive patients and by 14.4% in insulin-resistant patients. During thiazolidinedione therapy in a subgroup of insulin-resistant patients, insulin sensitivity improved, fasting plasma insulin levels decreased, and myocardial blood flow responses to cold pressor test normalized.

    Limitations: The study was not randomized, and it included only 1 ethnic group.

    Conclusions: Insulin-resistant patients who do not have hypercholesterolemia or hypertension and do not smoke manifest coronary vasomotor abnormalities. Insulin-sensitizing thiazolidinedione therapy normalized these abnormalities. These results suggest an association between insulin resistance and abnormal coronary vasomotor function, a relationship that requires confirmation in larger studies.

    Article and Author Information

    • Acknowledgments: The authors thank Drs. Alan Fogelman and Jerome Rotter for their critical review of this manuscript.

    • Grant Support: By National Institutes of Health grants HL33177 and 5PO1HL6003.

    • Potential Financial Conflicts of Interest:Consultancies: M.J. Quiñones (GlaxoSmithKline), W.A. Hsueh (Merck, GlaxoSmithKline, Novartis); Honoraria: M.J. Quiñones (GlaxoSmithKline), K. Van Herle (Novartis, GlaxoSmithKline, Takeda-Lilly); Grants received: M.J. Quiñones (GlaxoSmithKline), W.A. Hsueh (Merck, GlaxoSmithKline, Novartis, Takeda).

    • Requests for Single Reprints: Willa A. Hsueh, MD, Division of Endocrinology, Diabetes and Hypertension, David Geffen School of Medicine at University of California, Los Angeles, 900 Veteran Avenue, Suite 24-130, Los Angeles, CA 90095; e-mail, whsueh{at}mednet.ucla.edu.

    • Current Author Addresses: Drs. Quiñones, Bulnes-Enriquez, Jimenez, Van Herle, and Hsueh and Ms. De La Rosa: Division of Endocrinology, Diabetes and Hypertension, David Geffen School of Medicine at University of California, Los Angeles, 900 Veteran Avenue, Suite 24-130, Los Angeles, CA 90095.

    • Dr. Hernandez-Pampaloni: Department of Radiology, Children's Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Philadelphia, PA 19104.

    • Dr. Schelbert: Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, B2-085J, CHS Box 95648, 650 Charles E. Young Drive South, Los Angeles, CA 90095-6948.

    • Drs. Hernandez, Modilevsky, and Yu: Department of Medicine, Olive View–University of California, Los Angeles Medical Center, Room 2B182, 14445 Olive View Drive, Sylmar, CA 91342.

    • Drs. Chon and Elashoff: Department of Biomathematics, David Geffen School of Medicine at University of California, Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095-1766.

    • Dr. Yang: Division of Medical Genetics, Departments of Pediatrics, Steven Spielberg Pediatric Research Center, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048.

    • Dr. Nicholas: Division of Nephrology and Division of Endocrinology, Diabetes and Hypertension, David Geffen School of Medicine at University of California, Los Angeles, 900 Veteran Avenue, Suite 24-130, Los Angeles, CA 90095.

    • Dr. Castellani: Division of Cardiology, David Geffen School of Medicine at University of California, Los Angeles, 10833 Le Conte Avenue, 547-123 CHS, Los Angeles, CA 90095.

    • Author Contributions: Conception and design: M.J. Quiñones, W.A. Hsueh.

    • Analysis and interpretation of the data: M.J. Quiñones, M. Hernandez-Pampaloni, H. Schelbert, Y. Chon, H. Yang, R. Elashoff, W.A. Hsueh.

    • Drafting of the article: M.J. Quiñones, W.A. Hsueh.

    • Critical revision of the article for important intellectual content: M.J. Quiñones, M. Hernandez-Pampaloni, H. Schelbert, Y. Chon, S.B. Nicholas, R. Elashoff, W.A. Hsueh.

    • Final approval of the article: M.J. Quiñones, M. Hernandez-Pampaloni, H. Schelbert, W.A. Hsueh.

    • Provision of study materials or patients: M.J. Quiñones, I. Bulnes-Enriquez, X. Jimenez, G. Hernandez, R. De La Rosa, T. Modilevsky, K. Yu, K. Van Herle, W.A. Hsueh.

    • Statistical expertise: M.J. Quiñones, Y. Chon, H. Yang, R. Elashoff, W.A. Hsueh.

    • Obtaining of funding: W.A. Hsueh.

    • Administrative, technical, or logistic support: M.J. Quiñones, M. Hernandez-Pampaloni, I. Bulnes-Enriquez, X. Jimenez, G. Hernandez, R. De La Rosa, S.B. Nicholas, K. Van Herle, L.W. Castellani, W.A. Hsueh.

    • Collection and assembly of data: M.J. Quiñones, M. Hernandez-Pampaloni, I. Bulnes-Enriquez, X. Jimenez, G. Hernandez, R. De La Rosa, Y. Chon, H. Yang, L.W. Castellani, W.A. Hsueh.

    Summary for Patients

    • Summaries for Patients:Insulin Resistance Is Associated with Abnormalities of Coronary Arteries in People without Other Cardiac Risk Factors Ann Intern Med May 4, 2004 140:I-32
    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med May 4, 2004 vol. 140 no. 9 700-708
    1. » Abstract
    2. Full Text
    3. Full Text (PDF)
      1. Summary for Patients

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. November 3, 2009, 151 (9)
    1. Alert me to current issues